title: Does HIV-1 subtype D have a higher risk of vertical transmission than other HIV subtypes?
authors.forename: Anne
authors.initials: A
authors.lastname: Krivine
authors.forename: Odile
authors.initials: O
authors.lastname: Launay
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Firtion
authors.forename: Laurent
authors.initials: L
authors.lastname: Finkielsztejn
authors.forename: Vincent
authors.initials: V
authors.lastname: Jullien
authors.forename: Flore
authors.initials: F
authors.lastname: Rozenberg
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Pannier
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control / Q000635:transmission*; D015497:HIV-1 / Q000145:classification* / Q000472:pathogenicity; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000821:virology*; D011744:Pyrimidinones / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir; D019259:Lamivudine